JPMorgan on EyePoint Pharmaceuticals, Inc. (EYPT): 'We are pleased to see EyePoint’s continued execution'
Tweet Send to a Friend
JPMorgan analyst Tessa Romero reiterated an Overweight rating and $26.00 price target on EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
